Substituted pyrrolopyrimidines as HDM2 inhibitors
US9637493B2 · kind B2 · utility
0Cited by
2References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 18, 2013 |
| Grant date | May 2, 2017 |
| Priority date | — |
| Expiry date | Dec 18, 2033 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention provides substituted pyrrolopyrimidines of Formula I as described herein or a pharmaceutically acceptable salt or solvate thereof:The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.